Retinoblastoma (RB), which represents the most common childhood eye cancer, is caused by biallelic inactivation of RB1 gene. Promoter hypermethylation is quite frequent in RB tissues but conclusive evidence of soma-wide predisposing epimutations is currently scant. Here, 50 patients who tested negative for RB1 germline sequence alterations were screened for aberrant promoter methylation using methylation-specific MLPA. The assay, performed on blood, identified a sporadic patient with methylation of CpG106, absent in parents’ DNA. Bisulfite pyrosequencing accurately quantified CpG methylation in blood DNA (mean ∼49%) and also confirmed the aberration in DNA isolated from oral mucosa although at lower levels (mean ∼34%). Using a tag-SNP, methylation was demonstrated to affect the maternal allele. Real-time qPCR demonstrated RB1 transcriptional silencing. In conclusion, we documented that promoter methylation can act as the first “hit” in Knudson's model. This mosaic epimutation mimics the effect of an inactivating mutation and phenocopies RB onset.

Gelli, E., Pinto, A.M., Somma, S., Imperatore, V., Cannone, M.G., Hadjistilianou, T., et al. (2019). Evidence of predisposing epimutation in retinoblastoma. HUMAN MUTATION, 40(2), 201-206 [10.1002/humu.23684].

Evidence of predisposing epimutation in retinoblastoma

Gelli, Elisa;Pinto, Anna Maria;Somma, Serena;Imperatore, Valentina;Hadjistilianou, Theodora;De Francesco, Sonia;Galimberti, Daniela;CURRO', AURORA;Bruttini, Mirella;Mari, Francesca;Renieri, Alessandra;Ariani, Francesca
2019-01-01

Abstract

Retinoblastoma (RB), which represents the most common childhood eye cancer, is caused by biallelic inactivation of RB1 gene. Promoter hypermethylation is quite frequent in RB tissues but conclusive evidence of soma-wide predisposing epimutations is currently scant. Here, 50 patients who tested negative for RB1 germline sequence alterations were screened for aberrant promoter methylation using methylation-specific MLPA. The assay, performed on blood, identified a sporadic patient with methylation of CpG106, absent in parents’ DNA. Bisulfite pyrosequencing accurately quantified CpG methylation in blood DNA (mean ∼49%) and also confirmed the aberration in DNA isolated from oral mucosa although at lower levels (mean ∼34%). Using a tag-SNP, methylation was demonstrated to affect the maternal allele. Real-time qPCR demonstrated RB1 transcriptional silencing. In conclusion, we documented that promoter methylation can act as the first “hit” in Knudson's model. This mosaic epimutation mimics the effect of an inactivating mutation and phenocopies RB onset.
2019
Gelli, E., Pinto, A.M., Somma, S., Imperatore, V., Cannone, M.G., Hadjistilianou, T., et al. (2019). Evidence of predisposing epimutation in retinoblastoma. HUMAN MUTATION, 40(2), 201-206 [10.1002/humu.23684].
File in questo prodotto:
File Dimensione Formato  
Evidence of predisposing epimutation-Gelli_et_al-2019.pdf

non disponibili

Tipologia: PDF editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 744.3 kB
Formato Adobe PDF
744.3 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
ARIANI-Evidence of predisposing-AM-Post--Print.pdf

accesso aperto

Descrizione: Accepted Manuscript
Tipologia: Post-print
Licenza: PUBBLICO - Pubblico con Copyright
Dimensione 1.14 MB
Formato Adobe PDF
1.14 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1071570